改善脑血循环的措施主要有溶栓、抗血小板、抗凝、降纤和扩容等方法。第2代溶栓药物以组织纤溶酶原激活剂（tPA）的阿替普酶和尿激酶原为代表。阿替普酶是迄今为止美国FDA批准的唯一一款可用于治疗脑卒中的溶栓药。目前已发展至重组人组织型纤溶酶原激活剂（rtPA）的第3代溶栓药物，rtPA代表性药物有瑞替普酶、替奈普酶等，这些药物目前多数处于临床试验阶段。
瑞替普酶通过激活纤维蛋白溶解酶原行程纤溶酶，继而溶解纤维蛋白，成为可溶性的纤维蛋白降解产物，达到溶栓的目的。适用于成人由冠状动脉梗塞引起的急性心肌梗塞的溶栓疗法，能够改善心肌梗塞后的心室功能。本药应在症状发生后12小时内，尽可能早期使用。发病后6小时内比发病后7-12小时之间使用，治疗效果更好。瑞替普酶可以渗透性溶栓，溶栓速度更快，半衰期更长（12～16min），可静脉推注给药。
The basic information of drug
Common name: Reteplase
Indications: Thrombolytic therapy for acute myocardial infarction induced by coronary infarction. It can improve ventricular function after myocardial infarction.
Market demand
The measures to improve the blood circulation of the brain mainly include thrombolytic, antiplatelet, anticoagulant, reducing fiber and ampliation. The second generation thrombolytic drugs were represented by the atinase and urokinase of the plasminogen activator (tPA). The altipase is the only thrombolytic drug approved by the FDA to treat stroke so far. The third generation of thrombolytic drugs has been developed to recombinant human tissue plasminogen activator (rtPA). The representative drugs of rtPA include ritipase, tienase, etc. Most of these drugs are currently in clinical trials.
Ritipase is a soluble fibrinolytic enzyme that can dissolve fibrinolytic enzyme by activating fibrinolytic enzyme. It is suitable for the thrombolytic therapy of acute myocardial infarction caused by coronary artery infarction in adults and can improve the ventricular function after myocardial infarction. This drug should be used as early as possible within 12 hours after the onset of symptoms. The therapeutic effect was better in 6 hours after onset than 7-12 hours after onset. Retipase can permeate thrombolytic, thrombolytic speed is faster, the half-life is longer (12 ~ 16min), but intravenous injection of medicine.
（瑞替普酶作用机制，图片来源医博士）
